Verge Genomics is developing therapies for neurological diseases with a unique all-in-human platform. Advances in the generation of genomic data from patients are rapidly promoting our understanding of the biology of CNS diseases, allowing for the identification of previously undefined disease targets using computational methods. We de-risk these targets in patient-derived neurons in the laboratory to generate first-in-class small molecules. Using this methodology, we have created a robust pipeline of potential therapeutics in early development for many diseases, including amyotrophic lateral sclerosis (ALS) and Parkinson’s disease.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Robust pipeline of potential therapeutics for many diseases, including for ALS & Parkinson's.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):